Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | BCL6 | P41182 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22866360 | 0.98 | KMT2A (0.97) | KMT2AAXLBCL6ALDH1A1L3MBTL1 | |
| SCHEMBL1934273 | 0.95 | KMT2A (0.91) | KMT2AAXLBCL6ALDH1A1L3MBTL1 | |
| SCHEMBL1937922 | 0.92 | KMT2A (0.84) | KMT2AAXLBCL6ALDH1A1L3MBTL1 | |
| SCHEMBL13666836 | 0.84 | KMT2A (0.73) | KMT2AAXLALDH1A1L3MBTL1 | |
| SCHEMBL12526937 | 0.84 | KMT2A (0.73) | KMT2AAXLBCL6ALDH1A1L3MBTL1 | |
| SCHEMBL1937546 | 0.83 | KMT2A (0.71) | KMT2AAXLADORA3ADORA1ADORA2A | |
| Hydrochloric Acid SCHEMBL1748456 | 0.83 | KMT2A (0.71) | KMT2AAXLBCL6ALDH1A1L3MBTL1 | |
| SCHEMBL9977770 | 0.83 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL17518644 | 0.83 | KMT2A (0.70) | KMT2AAXLALDH1A1L3MBTL1ADORA3 | |
| SCHEMBL22247489 | 0.83 | KMT2A (0.70) | KMT2AAXLBCL6ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008791-A1 | CHEMICAL COMPOUNDS | BORAH INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12358932-B2 | Chemical compounds | BORAH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240368196-A1 | CHEMICAL COMPOUNDS | BORAH, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-114341145-B | Chemical compound | 博拉公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-3994142-A1 | CHEMICAL COMPOUNDS | Borah, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114341145-A | Chemical compound | 博拉公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2021003501-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003501-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2021-01-07 | — | — | WO | disclosed |
| EP-3405466-B1 | ARYL SUBSTITUTED PYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-11-18 | — | — | EP | disclosed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293521-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7060827-B2 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008791-A1 | CHEMICAL COMPOUNDS | JAK3, JAK2, JAK1 | KMT2A 1919/4885AXL 905/4885BCL6 49/4885 |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KMT2A 2984/4885AXL 505/4885BCL6 1028/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | KMT2A 1886/4885AXL 1688/4885BCL6 1268/4885 |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | FCER2, SYK, FCGR1A | KMT2A 3461/4885AXL 173/4885BCL6 946/4885 |
| US-20240368196-A1 | CHEMICAL COMPOUNDS | PDE4A, PDE4B, SYK | KMT2A 1015/4885AXL 391/4885BCL6 770/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | KMT2A 2086/4885AXL 1020/4885BCL6 636/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | KMT2A 4638/4885AXL 1064/4885BCL6 505/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | KMT2A 2984/4885AXL 505/4885BCL6 1028/4885 |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | HRH4, FCER2, HRH2 | KMT2A 2883/4885AXL 947/4885BCL6 877/4885 |
| US-20070293521-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | FCER2, SYK, FCGR1A | KMT2A 3461/4885AXL 173/4885BCL6 946/4885 |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | SYK, FCER2, FCGR1A | KMT2A 3199/4885AXL 77/4885BCL6 419/4885 |
| US-12358932-B2 | Chemical compounds | PDE4A, PDE4B, SYK | KMT2A 1015/4885AXL 391/4885BCL6 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.